vs
Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Organon & Co. (OGN). Click either name above to swap in a different company.
Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $950.5M, roughly 1.6× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -13.6%, a 14.3% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -5.3%). Organon & Co. produced more free cash flow last quarter ($96.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -3.6%).
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
ASTH vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $950.5M | $1.5B |
| Net Profit | $6.6M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | 1.9% | -9.8% |
| Net Margin | 0.7% | -13.6% |
| Revenue YoY | 42.9% | -5.3% |
| Net Profit YoY | 184.4% | -288.1% |
| EPS (diluted) | $0.12 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $950.5M | $1.5B | ||
| Q3 25 | $956.0M | $1.6B | ||
| Q2 25 | $654.8M | $1.6B | ||
| Q1 25 | $620.4M | $1.5B | ||
| Q4 24 | $665.2M | $1.6B | ||
| Q3 24 | $478.7M | $1.6B | ||
| Q2 24 | $486.3M | $1.6B | ||
| Q1 24 | $404.4M | $1.6B |
| Q4 25 | $6.6M | $-205.0M | ||
| Q3 25 | $373.0K | $160.0M | ||
| Q2 25 | $9.4M | $145.0M | ||
| Q1 25 | $6.7M | $87.0M | ||
| Q4 24 | $-7.8M | $109.0M | ||
| Q3 24 | $16.1M | $359.0M | ||
| Q2 24 | $19.2M | $195.0M | ||
| Q1 24 | $14.8M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | 1.9% | -9.8% | ||
| Q3 25 | 2.0% | 15.2% | ||
| Q2 25 | 3.1% | 14.4% | ||
| Q1 25 | 3.3% | 6.7% | ||
| Q4 24 | 0.1% | 8.1% | ||
| Q3 24 | 5.9% | 13.1% | ||
| Q2 24 | 6.2% | 14.6% | ||
| Q1 24 | 7.5% | 14.5% |
| Q4 25 | 0.7% | -13.6% | ||
| Q3 25 | 0.0% | 10.0% | ||
| Q2 25 | 1.4% | 9.1% | ||
| Q1 25 | 1.1% | 5.8% | ||
| Q4 24 | -1.2% | 6.8% | ||
| Q3 24 | 3.4% | 22.7% | ||
| Q2 24 | 3.9% | 12.1% | ||
| Q1 24 | 3.7% | 12.4% |
| Q4 25 | $0.12 | $-0.78 | ||
| Q3 25 | $0.01 | $0.61 | ||
| Q2 25 | $0.19 | $0.56 | ||
| Q1 25 | $0.14 | $0.33 | ||
| Q4 24 | $-0.14 | $0.42 | ||
| Q3 24 | $0.33 | $1.38 | ||
| Q2 24 | $0.40 | $0.75 | ||
| Q1 24 | $0.31 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $429.5M | $574.0M |
| Total DebtLower is stronger | — | $8.6B |
| Stockholders' EquityBook value | $779.3M | $752.0M |
| Total Assets | $2.2B | $12.9B |
| Debt / EquityLower = less leverage | — | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $429.5M | $574.0M | ||
| Q3 25 | $463.4M | $672.0M | ||
| Q2 25 | $342.1M | $599.0M | ||
| Q1 25 | $260.9M | $547.0M | ||
| Q4 24 | $290.8M | $675.0M | ||
| Q3 24 | $350.3M | $763.0M | ||
| Q2 24 | $327.7M | $704.0M | ||
| Q1 24 | $337.3M | $575.0M |
| Q4 25 | — | $8.6B | ||
| Q3 25 | — | $8.8B | ||
| Q2 25 | — | $8.9B | ||
| Q1 25 | — | $9.0B | ||
| Q4 24 | — | $8.9B | ||
| Q3 24 | — | $8.7B | ||
| Q2 24 | — | $8.7B | ||
| Q1 24 | — | $8.7B |
| Q4 25 | $779.3M | $752.0M | ||
| Q3 25 | $775.5M | $906.0M | ||
| Q2 25 | $765.5M | $733.0M | ||
| Q1 25 | $745.4M | $542.0M | ||
| Q4 24 | $712.7M | $472.0M | ||
| Q3 24 | $704.6M | $493.0M | ||
| Q2 24 | $678.9M | $144.0M | ||
| Q1 24 | $653.5M | $48.0M |
| Q4 25 | $2.2B | $12.9B | ||
| Q3 25 | $2.2B | $13.6B | ||
| Q2 25 | $1.4B | $13.5B | ||
| Q1 25 | $1.3B | $13.2B | ||
| Q4 24 | $1.4B | $13.1B | ||
| Q3 24 | $1.3B | $12.8B | ||
| Q2 24 | $1.3B | $12.2B | ||
| Q1 24 | $1.2B | $11.9B |
| Q4 25 | — | 11.49× | ||
| Q3 25 | — | 9.74× | ||
| Q2 25 | — | 12.14× | ||
| Q1 25 | — | 16.52× | ||
| Q4 24 | — | 18.81× | ||
| Q3 24 | — | 17.75× | ||
| Q2 24 | — | 60.11× | ||
| Q1 24 | — | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.9M | $141.0M |
| Free Cash FlowOCF − Capex | $-6.0M | $96.0M |
| FCF MarginFCF / Revenue | -0.6% | 6.4% |
| Capex IntensityCapex / Revenue | 0.3% | 3.0% |
| Cash ConversionOCF / Net Profit | -0.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | $104.5M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.9M | $141.0M | ||
| Q3 25 | $10.0M | $264.0M | ||
| Q2 25 | $90.9M | $220.0M | ||
| Q1 25 | $16.6M | $75.0M | ||
| Q4 24 | $-10.9M | $390.0M | ||
| Q3 24 | $34.0M | $141.0M | ||
| Q2 24 | $23.2M | $332.0M | ||
| Q1 24 | $6.0M | $76.0M |
| Q4 25 | $-6.0M | $96.0M | ||
| Q3 25 | $7.4M | $218.0M | ||
| Q2 25 | $89.5M | $181.0M | ||
| Q1 25 | $13.6M | $43.0M | ||
| Q4 24 | $-13.5M | $335.0M | ||
| Q3 24 | $31.7M | $99.0M | ||
| Q2 24 | $20.4M | $300.0M | ||
| Q1 24 | $5.6M | $30.0M |
| Q4 25 | -0.6% | 6.4% | ||
| Q3 25 | 0.8% | 13.6% | ||
| Q2 25 | 13.7% | 11.4% | ||
| Q1 25 | 2.2% | 2.8% | ||
| Q4 24 | -2.0% | 21.0% | ||
| Q3 24 | 6.6% | 6.3% | ||
| Q2 24 | 4.2% | 18.7% | ||
| Q1 24 | 1.4% | 1.8% |
| Q4 25 | 0.3% | 3.0% | ||
| Q3 25 | 0.3% | 2.9% | ||
| Q2 25 | 0.2% | 2.4% | ||
| Q1 25 | 0.5% | 2.1% | ||
| Q4 24 | 0.4% | 3.5% | ||
| Q3 24 | 0.5% | 2.7% | ||
| Q2 24 | 0.6% | 2.0% | ||
| Q1 24 | 0.1% | 2.8% |
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 1.65× | ||
| Q2 25 | 9.65× | 1.52× | ||
| Q1 25 | 2.48× | 0.86× | ||
| Q4 24 | — | 3.58× | ||
| Q3 24 | 2.11× | 0.39× | ||
| Q2 24 | 1.21× | 1.70× | ||
| Q1 24 | 0.40× | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
OGN
Segment breakdown not available.
